Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of radiation therapy oncology group 90-15

Abstract

For patients with unresectable nonsmall cell lung cancer, who were not selected on the basis of weight loss, concurrent hyperfractionated irradiation and chemotherapy had more intense acute toxicity than hyperfractionation alone, but late toxicity was acceptable. One and 2-year survival rates were 54 and 28%, respectively.